Welcome to our dedicated page for BESM news (Ticker: BESM), a resource for investors and traders seeking the latest updates and insights on BESM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BESM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BESM's position in the market.
BioTissue (NASDAQ: BESM) completed the sale of its non-ocular Surgical and Wound Care business to BioStem (OTC: BSEM) on Jan 21, 2026. BioStem acquired exclusive rights to the Neox and Clarix product lines, and BioTissue's Surgical sales team and key support staff will join BioStem's commercial organization. BioTissue will continue manufacturing those products for BioStem while refocusing its commercial strategy on ocular therapies, including Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard. Management frames the divestiture as a move to concentrate resources on eye care innovation and professional education.
